98%
921
2 minutes
20
Purpose: This study investigated the differences in global cerebral hemodynamics between the tremor-dominant (TD) and akinetic-rigid-dominant (ARD) subtypes of Parkinson's disease (PD) using multi-delay pseudo-continuous arterial spin labeling (MD-pCASL) imaging and evaluated the clinical value of MD-pCASL for identifying PD subtypes.
Methods: Twenty-five healthy controls (HC) and fifty-one patients with PD were enrolled: 26 in the TD group and 25 in the ARD group. Voxel-based analysis was performed to compare cerebral blood flow (CBF), arterial transit time (ATT), and cerebral blood volume (CBV) among the ARD, TD, and HC groups. Binary logistic regression analysis was used to screen independent influencing factors for predicting motor subtypes; a receiver operating characteristic curve was drawn to evaluate the diagnostic value of the multi-parameter arterial spin labeling (ASL) technique.
Results: Compared with the HC group, the ARD group exhibited increased CBF in the left thalamus, lingual gyrus, and hippocampus. Decreased CBF was observed in the left angular gyrus. The TD group exhibited decreased CBF in the left precuneus compared with that in the HC group. Compared with the TD group, the ARD group exhibited increased CBF in the left putamen, lingual gyrus, and hippocampus. Differences in CBV mirrored CBF trends. ATT prolongation was observed in the left middle temporal gyrus in the ARD group. Diagnosing ARD as positive, the following were considered potential risk factors: increased CBF in the left putamen and left lingual gyrus, increased CBV in the left lingual gyrus, and prolonged ATT in the left middle temporal gyrus. The combined areas under the curve of all indexes were 0.942; the optimal critical value was 0.766; sensitivity was 92%; and specificity was 84.6%.
Conclusion: Both subtypes exhibited hypoperfusion patterns predominantly in the parieto-occipital cortex, whereas patients with ARD uniquely displayed hyperperfusion within the basal ganglia nuclei. Moreover, multi-parameter ASL showed high diagnostic efficiency in distinguishing the two subtypes. These findings highlight MD-pCASL as a valuable tool for PD subtyping and therapeutic monitoring.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12263930 | PMC |
http://dx.doi.org/10.3389/fnhum.2025.1617996 | DOI Listing |
Ann Rheum Dis
September 2025
Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands.
Objectives: This study aims to develop recommendations on reporting baseline features and outcomes from axial spondyloarthritis (axSpA) clinical trials based on the recently updated instrument set of the Assessment of SpondyloArthritis international Society (ASAS) core outcome set (COS).
Methods: A steering group (SG) convened a workgroup (WG), consisting of 13 ASAS members including rheumatologists, methodologists, epidemiologists, and 2 Young ASAS members. Recommendations on reporting axSpA trials baseline features and outcomes were developed in 3 steps: (1) the SG identified relevant baseline features from key axSpA clinical trials and formulated a proposal on how outcomes related to the instruments in the ASAS COS should be presented.
Ann Rheum Dis
September 2025
Department of Pediatrics, Division of Rheumatology, University of Michigan, Ann Arbor, MI, USA.
Objectives: Juvenile dermatomyositis (JDM) is a heterogeneous autoimmune condition needing targeted treatment approaches and improved understanding of molecular mechanisms driving clinical phenotypes. We utilised exploratory proteomics from a longitudinal North American cohort of patients with new-onset JDM to identify biological pathways at disease onset and follow-up, tissue-specific disease activity, and myositis-specific autoantibody (MSA) status.
Methods: We measured 3072 plasma proteins (Olink panel) in 56 patients with JDM within 12 weeks of starting treatment (from the Childhood Arthritis and Rheumatology Research Alliance Registry and 3 additional sites) and 8 paediatric controls.
Ann Rheum Dis
September 2025
Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland; Department of Rheumatology, Oslo University Hospital, Oslo, Norway. Electronic address:
Background: Interstitial lung disease (ILD) is a frequent manifestation of connective tissue diseases (CTDs) and is associated with high morbidity and mortality. Clinical practice guidelines to standardise screening, diagnosis, treatment and follow-up for CTD-ILD are of high importance for optimised patient care.
Methods: A European Respiratory Society and European Alliance of Associations for Rheumatology task force committee, composed of pulmonologists, rheumatologists, pathologists, radiologists, methodologists and patient representatives, developed recommendations based on PICO (Patients, Intervention, Comparison, Outcomes) questions with grading of the evidence according to the GRADE (Grading of Recommendations, Assessment, Development and Evaluations) methodology and complementary narrative questions agreed on by both societies.
Ann Rheum Dis
September 2025
Immunogenetics Lab, Fundación Pública Galega de Medicina Xenómica, SERGAS, Grupo de Medicina Xenómica-USC, Instituto de investigación Sanitaria de Santiago de Compostela, Santiago de Compostela, Spain; Faculty of Health Sciences, Universidad Autónoma de Chile, Talca, Chile. Electronic address:
Objectives: This study aims to identify and validate a transcriptomic signature capable of predicting the response to tumour necrosis factor inhibitors (TNFi) therapy in patients with rheumatoid arthritis (RA) before treatment initiation.
Methods: We performed a retrospective transcriptomic analysis using 2 public datasets, RNA-seq data from peripheral blood mononuclear cells (GSE138746) and microarray data from whole blood (GSE33377), to define a small-scale gene signature predictive of the response to TNFi treatment. Three external validations were then conducted, resulting in a total of 279 individuals, 169 responders, and 110 nonresponders.
J Am Coll Cardiol
August 2025
National Institute of Cardiovascular Diseases (NICVD), Rafiqui Shaheed Road, Karachi- 75510, Pakistan.
Background: The first month post-primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) is the highest risk period for major adverse cardiovascular events (MACE), including stent thrombosis. Ticagrelor and double dose clopidogrel are effective antiplatelet therapies, but no head-to-head comparison exists in this setting.
Objectives: We sought to evaluate the efficacy of ticagrelor over twice daily clopidogrel in reducing MACE events within the first one month post primary PCI.